BRCA1/p220 loss triggers BRCA1-IRIS overexpression via mRNA stabilization in breast cancer cells
نویسندگان
چکیده
BRCA1/p220-assocaited and triple negative/basal-like (TN/BL) tumors are aggressive and incurable breast cancer diseases that share among other features the no/low BRCA1/p220 expression. Here we show that BRCA1/p220 silencing in normal human mammary epithelial (HME) cells reduces expression of two RNA-destabilizing proteins, namely AUF1 and pCBP2, both proteins bind and destabilize BRCA1-IRIS mRNA. BRCA1-IRIS overexpression in HME cells triggers expression of several TN/BL markers, e.g., cytokeratins 5 and 17, p-cadherin, EGFR and cyclin E as well as expression and activation of the pro-survival proteins; AKT and survivin. BRCA1-IRIS silencing in the TN/BL cell line, SUM149 or restoration of BRCA1/p220 expression in the mutant cell line, HCC1937 reduced expression of TN/BL markers, AKT and survivin and induced cell death. Collectively, we propose that BRCA1/p220 loss of expression or function triggers BRCA1-IRIS overexpression through a post-transcriptional mechanism, which in turn promotes formation of aggressive and invasive breast tumors by inducing expression of TN/BL and survival proteins.
منابع مشابه
BRCA1-IRIS Overexpression Promotes Formation of Aggressive Breast Cancers
INTRODUCTION Women with HER2(+) or triple negative/basal-like (TN/BL) breast cancers succumb to their cancer rapidly due, in part to acquired Herceptin resistance and lack of TN/BL-targeted therapies. BRCA1-IRIS is a recently discovered, 1399 residue, BRCA1 locus alternative product, which while sharing 1365 residues with the full-length product of this tumor suppressor gene, BRCA1/p220, it has...
متن کاملمیزان بیان پروتئینBRCA1 در کارسینوم های مهاجم و درجای پستان و ارتباط آن با مارکر سلول های بنیادی سرطان پستان (CD44) و عوامل پیش آگهی تومور
Introduction : Breast cancer is the most common cancer and the second cause of cancer death among women. Despite recent developments in therapeutic tools about 25% of all the involved cases die annually. The clinical, molecular, and pathologic features of breast cancer in BRCA1 mutation carriers suggest that BRCA1 may function as a stem-cell regulator. The purpose of the current study was to ...
متن کاملThe role of BRCA1-IRIS in ovarian cancer formation, drug resistance and progression
The BRCA1-IRIS protein was identified in 2004 [1] and later found to be frequently upregulated in multiple sporadic tumor types, including breast and ovarian cancers [2, 3]. In ovarian cancer samples, BRCA1-IRIS expression increases with tumor progression together with survivin [3]. This trend was positively correlated with significant decrease in the level of total FOXO1 and FOXO3a and increas...
متن کاملA1-IRIS Overexpression Promotes Cisplatin
Downlo sion of apoptosis plays a key role in cancer development, drug resistance, and recurrence. The locus product protein BRCA1-IRIS is overexpressed in several cisplatin-resistant ovarian cancer cell but its relationship to resistance is uncertain. Here, we show that in human ovarian surface epitheOSE) cells, overexpression of BRCA1-IRIS triggers expression of the antiapoptotic protein survi...
متن کاملBRCA1 overexpression sensitizes cancer cells to lovastatin via regulation of cyclin D1-CDK4-p21WAF1/CIP1 pathway: analyses using a breast cancer cell line and tumoral xenograft model.
It is well established that statins display potent anticancer activity in several types of proliferating tumor cells. However, how to promote the sensitivity of statins to mammary cancer is yet to be completely deciphered. The purpose of this study was to investigate whether breast cancer susceptibility gene 1 (BRCA1) overexpression sensitizes mammary cancer cells to statins. MCF-7 cells, which...
متن کامل